221 related articles for article (PubMed ID: 28358926)
41. SCCRO promotes glioma formation and malignant progression in mice.
Broderick SR; Golas BJ; Pham D; Towe CW; Talbot SG; Kaufman A; Bains S; Huryn LA; Yonekawa Y; Carlson D; Hambardzumyan D; Ramanathan Y; Singh B
Neoplasia; 2010 Jun; 12(6):476-84. PubMed ID: 20563250
[TBL] [Abstract][Full Text] [Related]
42. Simulating PDGF-Driven Glioma Growth and Invasion in an Anatomically Accurate Brain Domain.
Massey SC; Rockne RC; Hawkins-Daarud A; Gallaher J; Anderson ARA; Canoll P; Swanson KR
Bull Math Biol; 2018 May; 80(5):1292-1309. PubMed ID: 28842831
[TBL] [Abstract][Full Text] [Related]
43. Genetic modeling of gliomas in mice: new tools to tackle old problems.
Hambardzumyan D; Parada LF; Holland EC; Charest A
Glia; 2011 Aug; 59(8):1155-68. PubMed ID: 21305617
[TBL] [Abstract][Full Text] [Related]
44. A Tumor Suppressor Function for Notch Signaling in Forebrain Tumor Subtypes.
Giachino C; Boulay JL; Ivanek R; Alvarado A; Tostado C; Lugert S; Tchorz J; Coban M; Mariani L; Bettler B; Lathia J; Frank S; Pfister S; Kool M; Taylor V
Cancer Cell; 2015 Dec; 28(6):730-742. PubMed ID: 26669487
[TBL] [Abstract][Full Text] [Related]
45. Malignant transformation of bone marrow stromal cells induced by the brain glioma niche in rats.
He Q; Zou X; Duan D; Liu Y; Xu Q
Mol Cell Biochem; 2016 Jan; 412(1-2):1-10. PubMed ID: 26590986
[TBL] [Abstract][Full Text] [Related]
46. Platelet-derived growth factor beta is a potent inflammatory driver in paediatric high-grade glioma.
Ross JL; Chen Z; Herting CJ; Grabovska Y; Szulzewsky F; Puigdelloses M; Monterroza L; Switchenko J; Wadhwani NR; Cimino PJ; Mackay A; Jones C; Read RD; MacDonald TJ; Schniederjan M; Becher OJ; Hambardzumyan D
Brain; 2021 Feb; 144(1):53-69. PubMed ID: 33300045
[TBL] [Abstract][Full Text] [Related]
47. Mechanisms of glioma formation: iterative perivascular glioma growth and invasion leads to tumor progression, VEGF-independent vascularization, and resistance to antiangiogenic therapy.
Baker GJ; Yadav VN; Motsch S; Koschmann C; Calinescu AA; Mineharu Y; Camelo-Piragua SI; Orringer D; Bannykh S; Nichols WS; deCarvalho AC; Mikkelsen T; Castro MG; Lowenstein PR
Neoplasia; 2014 Jul; 16(7):543-61. PubMed ID: 25117977
[TBL] [Abstract][Full Text] [Related]
48. Loss of p53 cooperates with K-ras activation to induce glioma formation in a region-independent manner.
Muñoz DM; Tung T; Agnihotri S; Singh S; Guha A; Zadeh G; Hawkins C
Glia; 2013 Nov; 61(11):1862-72. PubMed ID: 24038521
[TBL] [Abstract][Full Text] [Related]
49. Non-contrast enhanced molecular characterization of C6 rat glioma tumor at 7 T.
Salehi Ravesh M; Huhndorf M; Moussavi A
Magn Reson Imaging; 2019 Sep; 61():175-186. PubMed ID: 31150813
[TBL] [Abstract][Full Text] [Related]
50. Bystander effect-mediated gene therapy of gliomas using genetically engineered neural stem cells.
Li S; Tokuyama T; Yamamoto J; Koide M; Yokota N; Namba H
Cancer Gene Ther; 2005 Jul; 12(7):600-7. PubMed ID: 15775995
[TBL] [Abstract][Full Text] [Related]
51. Patient‑derived orthotopic xenograft glioma models fail to replicate the magnetic resonance imaging features of the original patient tumor.
Xue W; Ton H; Zhang J; Xie T; Chen X; Zhou B; Guo Y; Fang J; Wang S; Zhang W
Oncol Rep; 2020 May; 43(5):1619-1629. PubMed ID: 32323818
[TBL] [Abstract][Full Text] [Related]
52. Characterization of microglia/macrophages in gliomas developed in S-100β-v-erbB transgenic rats.
Sasaki A; Yokoo H; Tanaka Y; Homma T; Nakazato Y; Ohgaki H
Neuropathology; 2013 Oct; 33(5):505-14. PubMed ID: 23331472
[TBL] [Abstract][Full Text] [Related]
53. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation.
Zheng H; Ying H; Yan H; Kimmelman AC; Hiller DJ; Chen AJ; Perry SR; Tonon G; Chu GC; Ding Z; Stommel JM; Dunn KL; Wiedemeyer R; You MJ; Brennan C; Wang YA; Ligon KL; Wong WH; Chin L; DePinho RA
Nature; 2008 Oct; 455(7216):1129-33. PubMed ID: 18948956
[TBL] [Abstract][Full Text] [Related]
54. Platelet-derived growth factor BB mediates the tropism of human mesenchymal stem cells for malignant gliomas.
Hata N; Shinojima N; Gumin J; Yong R; Marini F; Andreeff M; Lang FF
Neurosurgery; 2010 Jan; 66(1):144-56; discussion 156-7. PubMed ID: 20023545
[TBL] [Abstract][Full Text] [Related]
55. A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development.
Sherman-Baust CA; Kuhn E; Valle BL; Shih IeM; Kurman RJ; Wang TL; Amano T; Ko MS; Miyoshi I; Araki Y; Lehrmann E; Zhang Y; Becker KG; Morin PJ
J Pathol; 2014 Jul; 233(3):228-37. PubMed ID: 24652535
[TBL] [Abstract][Full Text] [Related]
56. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor.
Kambara H; Okano H; Chiocca EA; Saeki Y
Cancer Res; 2005 Apr; 65(7):2832-9. PubMed ID: 15805284
[TBL] [Abstract][Full Text] [Related]
57. The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.
Solga AC; Toonen JA; Pan Y; Cimino PJ; Ma Y; Castillon GA; Gianino SM; Ellisman MH; Lee DY; Gutmann DH
Oncotarget; 2017 Jul; 8(29):47206-47215. PubMed ID: 28525381
[TBL] [Abstract][Full Text] [Related]
58. Dependence of autocrine growth factor stimulation in platelet-derived growth factor-B-induced mouse brain tumor cells.
Uhrbom L; Hesselager G; Ostman A; Nistér M; Westermark B
Int J Cancer; 2000 Feb; 85(3):398-406. PubMed ID: 10652433
[TBL] [Abstract][Full Text] [Related]
59. Genetic characterization of commonly used glioma cell lines in the rat animal model system.
Sibenaller ZA; Etame AB; Ali MM; Barua M; Braun TA; Casavant TL; Ryken TC
Neurosurg Focus; 2005 Oct; 19(4):E1. PubMed ID: 16241103
[TBL] [Abstract][Full Text] [Related]
60. FasL gene knock-down therapy enhances the antiglioma immune response.
Jansen T; Tyler B; Mankowski JL; Recinos VR; Pradilla G; Legnani F; Laterra J; Olivi A
Neuro Oncol; 2010 May; 12(5):482-9. PubMed ID: 20406899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
